HematologyNews.net

Hematology Xagena

Search results for "Dexamethasone"

The IDMC ( Independent Data Monitoring Committee ) found a statistically significant improvement in time to disease progression in patients with multiple myeloma receiving Lenalidomide ( Revlimid ) pl ...


The FDA ( Food and Drug Administration ) approved a supplemental New Drug Application ( sNDA ) for Velcade ( Bortezomib ). This approval expands the label to include the treatment of patients with m ...


The European Commission has approved the use of Bortezomib ( Velcade ) for Injection as a second-line treatment in patients with multiple myeloma. Bortezomib is indicated as monotherapy for use in ...


Initial clinical results from Pivotal Phase III Special Protocol Assessment ( SPA ) trials using Revlimid ( Lenalidomide ) as a new approach in the treatment of heavily pretreated patients with relaps ...


Two phase II studies with Bortezomib ( Velcade ) showed very high response rates in front-line multiple myeloma. Overall response rates ranged from 88 to 95 percent with complete and near complete r ...


The results from the phase III APEX study have been published in The New England Journal of Medicine. The study showed Velcade ( Bortezomib ) was superior in survival, time to disease progression, an ...


Researchers from the University of Bologna, Italy, demonstrate that Thal-Dex ( Thalidomide used in combination with Dexamethasone ) is more powerful than conventional chemotherapy for the treatment of ...


Researchers at the Mayo Clinic Cancer Center demonstrated that combination therapy with Lenalidomide ( Revlimid ) and Dexamethasone looks like a breakthrough treatment for multiple myeloma. The combi ...


The combination of Thalidomide and Dexamethasone ( Thal/Dex ), when used as initial therapy for multiple myeloma, slowed disease progression almost two-fold compared to Dexamethasone alone. Mayo Cli ...


Preliminary results from a large, randomized clinical trial for patients with newly diagnosed multiple myeloma, has shown that the use of a low dose of the steroid Dexamethasone ( Decadron ), in combi ...


Researchers at the Johns Hopkins Kimmel Cancer Center have shown that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemothera ...


Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of ...


Novel treatments have shown improvements in survival and response rates for leukemia and lymphoma. The use of Dexamethasone early in the treatment of children with acute lymphoblastic leukemia, the ...


A phase III study is the first to prospectively determine that adding Rituximab ( MabThera, Rituxan ) to Dexamethasone is safe and effective in adult patients with previously untreated idiopathic thro ...


Four studies that highlight significant advances in treatment and survival outcomes for patients with various forms of thrombocytopenia, a group of bleeding disorders characterized by a low number of ...